Centre de recherche des Cordeliers INSERM, Sorbonne Université, Université de Paris
Personalized Medicine, Pharmacogenomics, Therapeutic OPtimization (MEPPOT) Team
15, rue de l’École de médecine
Hôpital Européen Georges Pompidou Pôle de biologie
20, rue Leblanc
Colorectal cancer (CRC) was one of the first cancers to be characterized from a molecular point of view. Initially divided into three molecular groups (chromosomal instability, microsatellite instability and methylator phenotype), CRC are now classified under four robust subtypes according to a consensual transcription-based molecular classification (“Consensus Molecular Subtypes”, CMS). These groups are firmly linked to biological, genomic and epigenetic characteristics, as well as survival rates. The CMS classification of CRC represents a major advance in our understanding of the molecular mechanisms behind the malignant transformation of colonic epithelial cells, and opens the way for development of a precision-based approach for this cancer.